CD71 expressing circulating neutrophils serve as a novel prognostic biomarker for metastatic spread and reduced outcome in pancreatic ductal adenocarcinoma patients.
Humans
Neutrophils
/ metabolism
Receptors, Transferrin
/ metabolism
Carcinoma, Pancreatic Ductal
/ pathology
Male
Antigens, CD
/ metabolism
Female
Pancreatic Neoplasms
/ pathology
Prognosis
Biomarkers, Tumor
/ metabolism
Middle Aged
Aged
Apyrase
/ metabolism
Interleukin-2 Receptor alpha Subunit
/ metabolism
Neoplasm Metastasis
Cytokines
/ metabolism
CD71
Metastatic spread
Neutrophils
Pancreatic ductal adenocarcinoma
Prognostic biomarker
Transferrin receptor 1
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
10 Sep 2024
10 Sep 2024
Historique:
received:
25
04
2024
accepted:
22
08
2024
medline:
11
9
2024
pubmed:
11
9
2024
entrez:
10
9
2024
Statut:
epublish
Résumé
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies, presenting a persisting global health burden. Neutrophils have a double-edged role in tumor progression exhibiting both pro-tumor and anti-tumor functions. CD71, also known as transferrin receptor 1, performs a critical role in cellular iron uptake and is highly expressed on proliferating cells, and especially on activated immune cells. CD71 is known to be elevated in various types of solid cancers and is associated with poor prognosis, however, the expression of CD71 on neutrophils in PDAC and its potential clinical impact is still unknown. Therefore, we analyzed CD71 on circulating neutrophils in PDAC and clinical control patients and found a significant increased expression in PDAC patients. High expression of CD71 on neutrophils in PDAC patients was associated with reduced outcome compared to low expression. CD71 on neutrophils correlated positively with the levels of proinflammatory cytokines IL-6, IFN-γ, and growth factor ligands CD40-L, and BAFF in plasma of PDAC patients. Finally, we have demonstrated that high expression of CD71 on neutrophils was also associated with an increased expression of CD39 and CD25 on circulating T-cells. Based on our findings, we hypothesize that CD71 on neutrophils is associated with tumor progression in PDAC. Further studies are required to investigate the distinct functionality of CD71 expressing neutrophils and their potential clinical application.
Identifiants
pubmed: 39256468
doi: 10.1038/s41598-024-70916-3
pii: 10.1038/s41598-024-70916-3
doi:
Substances chimiques
Receptors, Transferrin
0
CD71 antigen
0
Antigens, CD
0
Biomarkers, Tumor
0
Apyrase
EC 3.6.1.5
Interleukin-2 Receptor alpha Subunit
0
CD39 antigen
EC 3.6.1.5
IL2RA protein, human
0
ENTPD1 protein, human
EC 3.6.1.5
Cytokines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
21164Subventions
Organisme : Deutsche Forschungsgemeinschaft
ID : WE4892/8-1
Organisme : Deutsche Forschungsgemeinschaft
ID : WE4892/8-1
Organisme : Deutsche Forschungsgemeinschaft
ID : WE4892/8-1
Organisme : Deutsche Forschungsgemeinschaft
ID : WE4892/8-1
Organisme : Deutsche Forschungsgemeinschaft
ID : WE4892/8-1
Organisme : Deutsche Forschungsgemeinschaft
ID : WE4892/8-1
Organisme : Deutsche Forschungsgemeinschaft
ID : WE4892/8-1
Organisme : Deutsche Forschungsgemeinschaft
ID : WE4892/8-1
Organisme : Deutsche Forschungsgemeinschaft
ID : WE4892/8-1
Organisme : Deutsche Forschungsgemeinschaft
ID : WE4892/8-1
Organisme : Deutsche Forschungsgemeinschaft
ID : WE4892/8-1
Organisme : Deutsche Forschungsgemeinschaft
ID : WE4892/8-1
Organisme : Deutsche Forschungsgemeinschaft
ID : WE4892/8-1
Organisme : Deutsche Forschungsgemeinschaft
ID : WE4892/8-1
Organisme : Deutsche Forschungsgemeinschaft
ID : WE4892/8-1
Organisme : Deutsche Forschungsgemeinschaft
ID : WE4892/8-1
Organisme : Deutsche Forschungsgemeinschaft
ID : WE4892/8-1
Organisme : Deutsche Forschungsgemeinschaft
ID : WE4892/8-1
Organisme : Deutsche Forschungsgemeinschaft
ID : WE4892/8-1
Organisme : Deutsche Forschungsgemeinschaft
ID : WE4892/8-1
Organisme : Deutsche Forschungsgemeinschaft
ID : WE4892/8-1
Organisme : Deutsche Forschungsgemeinschaft
ID : WE4892/8-1
Organisme : Bundesministerium für Bildung und Forschung
ID : 03INT506CA
Organisme : Bundesministerium für Bildung und Forschung
ID : 03INT506CA
Organisme : Bundesministerium für Bildung und Forschung
ID : 03INT506CA
Organisme : Bundesministerium für Bildung und Forschung
ID : 03INT506CA
Organisme : Bundesministerium für Bildung und Forschung
ID : 03INT506CA
Organisme : Bundesministerium für Bildung und Forschung
ID : 03INT506CA
Organisme : Bundesministerium für Bildung und Forschung
ID : 03INT506CA
Organisme : Bundesministerium für Bildung und Forschung
ID : 03INT506CA
Organisme : Bundesministerium für Bildung und Forschung
ID : 03INT506CA
Organisme : Bundesministerium für Bildung und Forschung
ID : 03INT506CA
Organisme : Bundesministerium für Bildung und Forschung
ID : 03INT506CA
Organisme : Bundesministerium für Bildung und Forschung
ID : 03INT506CA
Organisme : Bundesministerium für Bildung und Forschung
ID : 03INT506CA
Organisme : Bundesministerium für Bildung und Forschung
ID : 03INT506CA
Organisme : Bundesministerium für Bildung und Forschung
ID : 03INT506CA
Organisme : Bundesministerium für Bildung und Forschung
ID : 03INT506CA
Organisme : Bundesministerium für Bildung und Forschung
ID : 03INT506CA
Organisme : Bundesministerium für Bildung und Forschung
ID : 03INT506CA
Organisme : Bundesministerium für Bildung und Forschung
ID : 03INT506CA
Organisme : Bundesministerium für Bildung und Forschung
ID : 03INT506CA
Organisme : Bundesministerium für Bildung und Forschung
ID : 03INT506CA
Organisme : Bundesministerium für Bildung und Forschung
ID : 03INT506CA
Informations de copyright
© 2024. The Author(s).
Références
Ilic, I. & Ilic, M. International patterns in incidence and mortality trends of pancreatic cancer in the last three decades: A joinpoint regression analysis. World J. Gastroenterol. 28(32), 4698–4715 (2022).
pubmed: 36157927
pmcid: 9476884
doi: 10.3748/wjg.v28.i32.4698
Permuth, J. B., Powers, B. D., Hodul, P. J. & Florida Pancreas, C. A path forward for understanding and addressing multifaceted pancreatic cancer disparities. Gastroenterology 163(1), 51–53 (2022).
pubmed: 35513007
doi: 10.1053/j.gastro.2022.04.047
Orth, M. et al. Pancreatic ductal adenocarcinoma: Biological hallmarks, current status, and future perspectives of combined modality treatment approaches. Radiat. Oncol. 14(1), 141 (2019).
pubmed: 31395068
pmcid: 6688256
doi: 10.1186/s13014-019-1345-6
Rahib, L. et al. Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 74(11), 2913–2921 (2014).
pubmed: 24840647
doi: 10.1158/0008-5472.CAN-14-0155
Hsu, S. K. et al. Culprits of PDAC resistance to gemcitabine and immune checkpoint inhibitor: Tumour microenvironment components. Front. Mol. Biosci. 9, 1020888 (2022).
pubmed: 36299300
pmcid: 9589289
doi: 10.3389/fmolb.2022.1020888
Jain, A. & Bhardwaj, V. Therapeutic resistance in pancreatic ductal adenocarcinoma: Current challenges and future opportunities. World J. Gastroenterol. 27(39), 6527–6550 (2021).
pubmed: 34754151
pmcid: 8554400
doi: 10.3748/wjg.v27.i39.6527
Quinonero, F. et al. The challenge of drug resistance in pancreatic ductal adenocarcinoma: A current overview. Cancer Biol. Med. 16(4), 688–699 (2019).
pubmed: 31908888
pmcid: 6936232
doi: 10.20892/j.issn.2095-3941.2019.0252
Jaillon, S. et al. Neutrophil diversity and plasticity in tumour progression and therapy. Nat. Rev. Cancer 20(9), 485–503 (2020).
pubmed: 32694624
doi: 10.1038/s41568-020-0281-y
McFarlane, A. J., Fercoq, F., Coffelt, S. B. & Carlin, L. M. Neutrophil dynamics in the tumor microenvironment. J. Clin. Invest. 131(6), 329 (2021).
doi: 10.1172/JCI143759
Masucci, M. T., Minopoli, M. & Carriero, M. V. Tumor Associated Neutrophils. Their role in tumorigenesis, metastasis, prognosis and therapy. Front. Oncol. 9, 1146 (2019).
pubmed: 31799175
pmcid: 6874146
doi: 10.3389/fonc.2019.01146
Kalafati, L., Mitroulis, I., Verginis, P., Chavakis, T. & Kourtzelis, I. Neutrophils as orchestrators in tumor development and metastasis formation. Front. Oncol. 10, 581457 (2020).
pubmed: 33363012
pmcid: 7758500
doi: 10.3389/fonc.2020.581457
Garcia-Mendoza, M. G. et al. Neutrophils drive accelerated tumor progression in the collagen-dense mammary tumor microenvironment. Breast Cancer Res. 18(1), 49 (2016).
pubmed: 27169366
pmcid: 4864897
doi: 10.1186/s13058-016-0703-7
Furumaya, C., Martinez-Sanz, P., Bouti, P., Kuijpers, T. W. & Matlung, H. L. Plasticity in pro- and anti-tumor activity of neutrophils: Shifting the balance. Front. Immunol. 11, 2100 (2020).
pubmed: 32983165
pmcid: 7492657
doi: 10.3389/fimmu.2020.02100
UstyanovskaAvtenyuk, N., Visser, N., Bremer, E. & Wiersma, V. R. The neutrophil: The underdog that packs a punch in the fight against cancer. Int. J. Mol. Sci. 21(21), 7820 (2020).
doi: 10.3390/ijms21217820
Albanesi, M. et al. Neutrophils mediate antibody-induced antitumor effects in mice. Blood 122(18), 3160–3164 (2013).
pubmed: 23980063
pmcid: 3814733
doi: 10.1182/blood-2013-04-497446
Zhu, Y. et al. Tissue-resident macrophages in pancreatic ductal adenocarcinoma originate from embryonic hematopoiesis and promote tumor progression. Immunity 47(2), 323–338 (2017).
pubmed: 28813661
pmcid: 5578409
doi: 10.1016/j.immuni.2017.07.014
Jeong, S. M., Hwang, S. & Seong, R. H. Transferrin receptor regulates pancreatic cancer growth by modulating mitochondrial respiration and ROS generation. Biochem. Biophys. Res. Commun. 471(3), 373–379 (2016).
pubmed: 26869514
doi: 10.1016/j.bbrc.2016.02.023
Daniels, T. R., Delgado, T., Rodriguez, J. A., Helguera, G. & Penichet, M. L. The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancer. Clin. Immunol. 121(2), 144–158 (2006).
pubmed: 16904380
doi: 10.1016/j.clim.2006.06.010
Falvo, E. et al. High activity and low toxicity of a novel CD71-targeting nanotherapeutic named The-0504 on preclinical models of several human aggressive tumors. J. Exp. Clin. Cancer Res. 40(1), 63 (2021).
pubmed: 33568214
pmcid: 7877078
doi: 10.1186/s13046-021-01851-8
Zhao, J. et al. Tumor-derived extracellular vesicles inhibit natural killer cell function in pancreatic cancer. Cancers (Basel) 11(6), 874 (2019).
pubmed: 31234517
doi: 10.3390/cancers11060874
Dinh, H. Q. et al. Coexpression of CD71 and CD117 identifies an early unipotent neutrophil progenitor population in human bone marrow. Immunity 53(2), 319–334 (2020).
pubmed: 32814027
pmcid: 7942809
doi: 10.1016/j.immuni.2020.07.017
Brierley, J., Gospodarowicz, M. K. & Wittekind, C. Ebscohost TNM Classification of Malignant Tumours 8th edn. (Wiley, 2017).
Sarhan, D. et al. Targeting myeloid suppressive cells revives cytotoxic anti-tumor responses in pancreatic cancer. iScience 25(11), 105317 (2022).
pubmed: 36310582
pmcid: 9615326
doi: 10.1016/j.isci.2022.105317
Hansen, F. J. et al. Circulating monocytes serve as novel prognostic biomarker in pancreatic ductal adenocarcinoma patients. Cancers (Basel) 15(2), 363 (2023).
pubmed: 36672313
doi: 10.3390/cancers15020363
Motamedi, M., Xu, L. & Elahi, S. Correlation of transferrin receptor (CD71) with Ki67 expression on stimulated human and mouse T cells: The kinetics of expression of T cell activation markers. J. Immunol. Methods 437, 43–52 (2016).
pubmed: 27555239
doi: 10.1016/j.jim.2016.08.002
Martins Castanheira, N., Spanhofer, A. K., Wiener, S., Bobe, S. & Schillers, H. Uptake of platelets by cancer cells and recycling of the platelet protein CD42a. J. Thromb. Haemost. 20(1), 170–181 (2022).
pubmed: 34592045
doi: 10.1111/jth.15543
Hedrick, C. C. & Malanchi, I. Neutrophils in cancer: Heterogeneous and multifaceted. Nat. Rev. Immunol. 22(3), 173–187 (2022).
pubmed: 34230649
doi: 10.1038/s41577-021-00571-6
Thommen, D. S. & Schumacher, T. N. T cell dysfunction in cancer. Cancer Cell 33(4), 547–562 (2018).
pubmed: 29634943
pmcid: 7116508
doi: 10.1016/j.ccell.2018.03.012
Yang, J. J. et al. Prognostic significance of neutrophil to lymphocyte ratio in pancreatic cancer: A meta-analysis. World J. Gastroenterol. 21(9), 2807–2815 (2015).
pubmed: 25759553
pmcid: 4351235
doi: 10.3748/wjg.v21.i9.2807
Antonioli, L., Pacher, P., Vizi, E. S. & Hasko, G. CD39 and CD73 in immunity and inflammation. Trends Mol. Med. 19(6), 355–367 (2013).
pubmed: 23601906
pmcid: 3674206
doi: 10.1016/j.molmed.2013.03.005
Chen, X. et al. CD4+CD25+ regulatory T cells in tumor immunity. Int. Immunopharmacol. 34, 244–249 (2016).
pubmed: 26994448
doi: 10.1016/j.intimp.2016.03.009
Benard, A. et al. Interleukin-3 protects against viral pneumonia in sepsis by enhancing plasmacytoid dendritic cell recruitment into the lungs and T cell priming. Front. Immunol. 14, 1140630 (2023).
pubmed: 36911737
pmcid: 9996195
doi: 10.3389/fimmu.2023.1140630
Carnevale, S. et al. Neutrophil diversity in inflammation and cancer. Front. Immunol. 14, 1180810 (2023).
pubmed: 37180120
pmcid: 10169606
doi: 10.3389/fimmu.2023.1180810
Wang, L. et al. Single-cell RNA-seq analysis reveals BHLHE40-driven pro-tumour neutrophils with hyperactivated glycolysis in pancreatic tumour microenvironment. Gut 72(5), 958–971 (2023).
pubmed: 35688610
doi: 10.1136/gutjnl-2021-326070
Kleven, M. D., Jue, S. & Enns, C. A. Transferrin receptors TfR1 and TfR2 bind transferrin through differing mechanisms. Biochemistry 57(9), 1552–1559 (2018).
pubmed: 29388418
doi: 10.1021/acs.biochem.8b00006
Kawabata, H. Transferrin and transferrin receptors update. Free Radic. Biol. Med. 133, 46–54 (2019).
pubmed: 29969719
doi: 10.1016/j.freeradbiomed.2018.06.037
Gammella, E., Buratti, P., Cairo, G. & Recalcati, S. The transferrin receptor: The cellular iron gate. Metallomics 9(10), 1367–1375 (2017).
pubmed: 28671201
doi: 10.1039/C7MT00143F
Ponka, P. & Lok, C. N. The transferrin receptor: Role in health and disease. Int. J. Biochem. Cell Biol. 31(10), 1111–1137 (1999).
pubmed: 10582342
doi: 10.1016/S1357-2725(99)00070-9
Santana-Codina, N. et al. NCOA4-mediated ferritinophagy is a pancreatic cancer dependency via maintenance of iron bioavailability for iron-sulfur cluster proteins. Cancer Discov. 12(9), 2180–2197 (2022).
pubmed: 35771492
pmcid: 9437572
doi: 10.1158/2159-8290.CD-22-0043
Gomme, P. T., McCann, K. B. & Bertolini, J. Transferrin: Structure, function and potential therapeutic actions. Drug Discov. Today 10(4), 267–273 (2005).
pubmed: 15708745
doi: 10.1016/S1359-6446(04)03333-1
Habashy, H. O. et al. Transferrin receptor (CD71) is a marker of poor prognosis in breast cancer and can predict response to tamoxifen. Breast Cancer Res. Treat. 119(2), 283–293 (2010).
pubmed: 19238537
doi: 10.1007/s10549-009-0345-x
Chan, K. T. et al. Overexpression of transferrin receptor CD71 and its tumorigenic properties in esophageal squamous cell carcinoma. Oncol. Rep. 31(3), 1296–1304 (2014).
pubmed: 24435655
doi: 10.3892/or.2014.2981
Leung, T. H. et al. CD71(+) Population enriched by HPV-E6 protein promotes cancer aggressiveness and radioresistance in cervical cancer cells. Mol. Cancer Res 17(9), 1867–1880 (2019).
pubmed: 31235657
doi: 10.1158/1541-7786.MCR-19-0068
Pylaeva, E. et al. During early stages of cancer, neutrophils initiate anti-tumor immune responses in tumor-draining lymph nodes. Cell Rep. 40(7), 111171 (2022).
pubmed: 35977505
doi: 10.1016/j.celrep.2022.111171
Tamassia, N. et al. Cytokine production by human neutrophils: Revisiting the “dark side of the moon”. Eur. J. Clin. Invest. 48(Suppl 2), e12952 (2018).
pubmed: 29772063
doi: 10.1111/eci.12952
Roshani, R., McCarthy, F. & Hagemann, T. Inflammatory cytokines in human pancreatic cancer. Cancer Lett. 345(2), 157–163 (2014).
pubmed: 23879960
doi: 10.1016/j.canlet.2013.07.014
Karakhanova, S. et al. Characterization of myeloid leukocytes and soluble mediators in pancreatic cancer: Importance of myeloid-derived suppressor cells. Oncoimmunology 4(4), e998519 (2015).
pubmed: 26137414
pmcid: 4485765
doi: 10.1080/2162402X.2014.998519
Pop, V. V., Seicean, A., Lupan, I., Samasca, G. & Burz, C. C. IL-6 roles: Molecular pathway and clinical implication in pancreatic cancer—A systemic review. Immunol. Lett. 181, 45–50 (2017).
pubmed: 27876525
doi: 10.1016/j.imlet.2016.11.010
Feng, R. et al. Nab-paclitaxel interrupts cancer-stromal interaction through C-X-C motif chemokine 10-mediated interleukin-6 downregulation in vitro. Cancer Sci. 109(8), 2509–2519 (2018).
pubmed: 29902349
pmcid: 6113502
doi: 10.1111/cas.13694
Ikeda, H., Old, L. J. & Schreiber, R. D. The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev. 13(2), 95–109 (2002).
pubmed: 11900986
doi: 10.1016/S1359-6101(01)00038-7
Kursunel, M. A. & Esendagli, G. The untold story of IFN-gamma in cancer biology. Cytokine Growth Factor Rev. 31, 73–81 (2016).
pubmed: 27502919
doi: 10.1016/j.cytogfr.2016.07.005
Aukrust, P. et al. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina: Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation 100(6), 614–620 (1999).
pubmed: 10441098
doi: 10.1161/01.CIR.100.6.614
Chung, H. W. & Lim, J. B. Clinical significance of elevated serum soluble CD40 ligand levels as a diagnostic and prognostic tumor marker for pancreatic ductal adenocarcinoma. J. Transl. Med. 12, 102 (2014).
pubmed: 24745825
pmcid: 4021610
doi: 10.1186/1479-5876-12-102
Ullah, M. A. & Mackay, F. The BAFF-APRIL system in cancer. Cancers (Basel) 15(6), 1791 (2023).
pubmed: 36980677
doi: 10.3390/cancers15061791
Koizumi, M. et al. Increased B cell-activating factor promotes tumor invasion and metastasis in human pancreatic cancer. PLoS One 8(8), e71367 (2013).
pubmed: 23940742
pmcid: 3735500
doi: 10.1371/journal.pone.0071367
Moesta, A. K., Li, X. Y. & Smyth, M. J. Targeting CD39 in cancer. Nat. Rev. Immunol. 20(12), 739–755 (2020).
pubmed: 32728220
doi: 10.1038/s41577-020-0376-4
Hansen, F. J. et al. Tumor infiltration with CD20(+)CD73(+) B cells correlates with better outcome in colorectal cancer. Int. J. Mol. Sci. 23(9), 5163 (2022).
pubmed: 35563553
pmcid: 9101418
doi: 10.3390/ijms23095163
Takenaka, M. C., Robson, S. & Quintana, F. J. Regulation of the T Cell Response by CD39. Trends Immunol. 37(7), 427–439 (2016).
pubmed: 27236363
pmcid: 5215082
doi: 10.1016/j.it.2016.04.009
Peng, Y. et al. CD25: A potential tumor therapeutic target. Int. J. Cancer 152(7), 1290–1303 (2023).
pubmed: 36082452
doi: 10.1002/ijc.34281
Ohue, Y. & Nishikawa, H. Regulatory T (Treg) cells in cancer: Can Treg cells be a new therapeutic target?. Cancer Sci. 110(7), 2080–2089 (2019).
pubmed: 31102428
pmcid: 6609813
doi: 10.1111/cas.14069